Abbott雅培在泰国获得首个地舒单抗生物类似药的监管批准,这将扩大骨病治疗的可及性。
Abbott雅培在泰国获得首个地舒单抗生物类似药的监管批准,这将扩大骨病治疗的可及性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.